2025-12-06 - Analysis Report
Okay, here's a comprehensive report on Eli Lilly and Co (LLY) based on the provided data.

**Eli Lilly and Co (LLY): Report**

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

**1. Return Rate Comparison with S&P 500 (VOO):**

*   **LLY Cumulative Return:** 291.31%
*   **VOO Cumulative Return:** 100.58%
*   **Divergence:**
    *   **Current:** 207.5
    *   **Relative Divergence:** 85.5

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the period covered by the cumulative returns. The current divergence of 207.5 indicates a substantial lead. The relative divergence of 85.5 suggests that the current outperformance is positioned in the top percentile (85.5%) of historical outperformance fluctuations, indicating very high performance recently.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2015-2017  | 11.0%   | 76.1%   | -17.0%  | -0.0 | 73.8   |
| 2016-2018  | 39.0%   | 68.9%   | 24.0%   | -0.0 | 101.1  |
| 2017-2019  | 41.0%   | 68.9%   | 19.0%   | 0.4   | 114.8  |
| 2018-2020  | 34.0%   | 79.8%   | 10.0%   | 0.4   | 147.5  |
| 2019-2021  | 53.0%   | 79.8%   | 7.0%    | 0.5   | 241.3  |
| 2020-2022  | 64.0%   | 79.8%   | 65.0%   | 0.4   | 319.6  |
| 2021-2023  | 125.0%  | 78.9%   | 124.0%  | 0.2   | 509.2  |
| 2022-2024  | 134.0%  | 81.2%   | 113.0%  | 0.2   | 674.4  |
| 2023-2025  | 183.0%  | 83.5%   | 118.0%  | 0.2   | 902.9  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate has consistently increased, especially in recent years, indicating strong growth.
*   **MDD:** The Maximum Drawdown remains high, suggesting considerable risk or volatility.
*   **Alpha:** Alpha is increasingly positive, demonstrating LLY's ability to generate returns above the benchmark (S&P 500).  The surge in Alpha in recent periods (2020-2025) reflects significant outperformance.
*   **Beta:** Beta remains low (close to 0) indicating that the stock has very low volatility relative to the market (S&P 500).
*   **Cap(B):** Market capitalization has grown substantially, indicating increasing investor confidence.

**2. Recent Stock Price Fluctuations:**

*   **Current Price:** 1033.56
*   **Last Market Close:** Price: 1007.34, Previous Close: 1014.49, Change: -0.71
*   **5-day SMA:** 1059.38
*   **20-day SMA:** 1024.51
*   **60-day SMA:** 876.08

**Analysis:** The current price is below both the 5-day SMA and the last market close, suggesting a short-term downward trend. However, it remains above the 20-day and 60-day SMAs, indicating a continued upward trend in the medium- to long-term. The recent price decrease (negative change in the last market close) implies a degree of volatility.

**3. RSI, PPO, and Divergence Analysis:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 54.19
*   **PPO:** -0.93
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90). Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent (20 days) relative divergence change:** 1.1 (+): 단기상승 (Short-term Rise)
*   **Expected Return (%):** 47.1%

**Analysis:**

*   The **MRI of 0.8** suggests a medium level of risk.
*   The **RSI of 54.19** indicates a neutral condition (neither overbought nor oversold).
*   The **PPO of -0.93** indicates that the short-term moving average is slightly below the long-term moving average, which is a bearish signal, but only slightly.
*   The **Hybrid Signal** suggests a strong buy signal with no cash allocation, indicating high confidence in the stock's potential. The MRI for the signal is 0.90, which still suggests a Medium Investment.
*   The **Recent relative divergence change** indicates a short-term upward trend, supporting the Hybrid signal.
*   The **Expected Return of 47.1%** is very attractive, suggesting significant potential for long-term investors.

**4. Recent News & Significant Events (Yahoo Finance):**

*   **Multiple Price Target Increases:** Analysts are raising price targets for LLY, signaling positive sentiment.
*   **Zepbound Price Cuts:** Eli Lilly's decision to cut prices for Zepbound could impact revenue but potentially increase market share. This could affect profitability and future growth.
*   **Trading Above SMAs:** The stock is trading above its 50-day and 200-day SMAs, reinforcing the longer-term bullish trend.
*   **Bull Case Theory:** There is an overall bullish sentiment surrounding Eli Lilly.

**Analysis:** The news is predominantly positive, with analysts raising price targets and bullish articles appearing. The price cuts for Zepbound may be a concern, but the overall sentiment suggests continued growth potential.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (~1.77)
*   **Target Price (avg/high/low):** 1056.70 / 1500.00 / 770.00
*   **Recent Rating Changes:** Not Provided

**Analysis:** The analyst consensus is a "Buy" with a mean rating of 1.77. The average target price of $1056.70 is slightly above the current price, suggesting further upside potential. The range of target prices is wide, reflecting varying opinions.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-10-30 | 6.22 | 17.60 B$  |
| 2025-08-07 | 6.30 | 15.56 B$  |
| 2025-05-01 | 3.07 | 12.73 B$  |
| 2024-10-30 | 1.08 | 11.44 B$  |
| 2025-10-30 | 1.08 | 11.44 B$  |

**Analysis:** Both EPS (Earnings Per Share) and Revenue have increased significantly over the past few quarters. This demonstrates strong financial performance and growth momentum. The EPS and revenue in 2025 are notably higher than in 2024, underscoring the positive trend. The most recent EPS of $6.22 and revenue of $17.60B point to continued success.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|---------------|
| 2025-09-30   | $17.60B     | 82.91%        |
| 2025-06-30   | $15.56B     | 84.27%        |
| 2025-03-31   | $12.73B     | 82.53%        |
| 2024-12-31   | $13.53B     | 82.24%        |
| 2024-09-30   | $11.44B     | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE      |
|--------------|-------------|----------|
| 2025-09-30   | $23.79B     | 23.46%   |
| 2025-06-30   | $18.27B     | 30.98%   |
| 2025-03-31   | $15.76B     | 17.50%   |
| 2024-12-31   | $14.19B     | 31.07%   |
| 2024-09-30   | $14.24B     | 6.81%    |

**Analysis:**

*   **Revenue and Profitability:** Revenue has been steadily increasing, indicating strong sales growth. The Profit Margin is consistently high, demonstrating the company's ability to convert revenue into profit efficiently.
*   **Capital and Profitability:** Equity has also been increasing, reflecting growing financial strength. ROE (Return on Equity) has been volatile, but generally high, showing the company's effectiveness in generating profit from shareholders' investments. The ROE of 31.07% in 2024-12-31 stands out, showcasing a high level of profitability relative to equity.

**7. Comprehensive Analysis (Summary):**

Eli Lilly and Co (LLY) demonstrates strong financial performance and growth potential. The company has significantly outperformed the S&P 500. Recent news and analyst opinions are generally positive, with several price target increases.  The company's revenue, profit margin, and ROE all indicate strong financial health. While there is some short-term downward pressure on the stock price (current price below 5-day SMA), the medium- to long-term trends remain bullish. The high expected return of 47.1% makes LLY an attractive investment for long-term investors. However, the relatively high MDD suggests that investors should be aware of the potential for volatility. The recent Zepbound price cuts should be monitored for their impact on future revenue and profitability. Overall, LLY appears to be a promising investment with continued growth prospects.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.